Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : STEM -- StemCells, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (211)	2/24/1999 8:17:00 AM
From: WWS	Read Replies (1) \| Respond to of 805

Mike, I'd suggest that we extricate CTII from automatic inclusion on lists of stem cell companies that also include GERN and Aastrom. Reason being that the latter two are developing procedures for allogenic (foreign) transplantation and thus must deal w/issues of potential rejection of the graft. Nothing intrinsic constrains CTII to dependence on allogenic mode, since their cell source (at least in theory) can be autologous (self). And because no fetal tissue is involved with autologous mode, one would also avoid the ethical issues confronting GERN (but not a problem with Aastrom's cord blood). The downside of autologous is that one has to deal with harvesting and ex-vivo expansion of tissue-specific stem cells. Although techniques for practical clinical harvesting and expansion are well developed for human hematopoeitic stem cells, I'm not sure how much comparable progress has been made for human neural stem cells.